💸 The Tape

The cannabis plant has over a hundred known cannabinoids. Most of the attention — and most of the research dollars — have gone to THC and CBD. But a quieter compound is starting to make noise in medical research circles, and its latest showing could have significant implications for the millions of people living with one of the most debilitating autoimmune conditions on the planet.

Cannabigerol (CBG), a non-intoxicating cannabinoid often called the "mother cannabinoid" because it serves as the chemical precursor to THC, CBD, and other compounds during the plant's growth cycle, is emerging as a potentially powerful anti-inflammatory agent. And according to a new preclinical study from Israel's Rambam Health Care Campus, CBG may represent a novel approach to treating rheumatoid arthritis (RA) — one that works through a mechanism no current therapy specifically targets.

What the Study Found

The research, published in the journal Pharmaceuticals, examined CBG's effects on neutrophils — a type of white blood cell that plays a central role in the inflammatory cascade associated with rheumatoid arthritis. While most conventional RA therapies target specific proteins called cytokines (the chemical messengers that drive inflammation), this study took a different approach by using CBG to directly regulate the immune cells that produce those cytokines in the first place.

The preclinical work involved two components: introducing CBG to isolated neutrophils extracted from human blood cells, and administering the compound to lab mice with induced arthritis.

The results were striking. In the human cell analysis, CBG reduced the inflammatory cytokine IL-6 by 98% and IL-1β by 60%. It also decreased MCP-1 by 22% and IL-1β by 38% in joint tissue. Perhaps most significantly, CBG made it less likely that neutrophils would migrate toward inflammatory signals — a process called chemotaxis that is a key driver of the joint damage cycle in RA. When immune cells stop flooding into joints, the destructive inflammatory loop begins to slow.

In the mouse model, subjects treated with CBG showed improved arthritic scores and were less likely to experience weight loss compared to untreated controls. The disease still manifested, but with notably less severity.

"These findings demonstrate that CBG exerts a regulatory effect by limiting inflammatory immune cell recruitment to inflamed joints," the researchers wrote, concluding that "CBG has anti-inflammatory capacity and therapeutic potential in regulating neutrophil-mediated immunity in RA."

Why This Matters

Rheumatoid arthritis affects an estimated 1.3 million Americans and tens of millions worldwide. It's a chronic autoimmune condition in which the body's immune system attacks its own joint tissue, causing pain, swelling, stiffness, and progressive joint destruction. Current treatments — including NSAIDs, corticosteroids, DMARDs (disease-modifying antirheumatic drugs), and biologic agents — focus primarily on suppressing the immune system broadly or blocking specific cytokines downstream.

What none of them do, according to the study authors, is specifically target neutrophils. That's the gap CBG may be able to fill. By going upstream — regulating the immune cells themselves rather than just the proteins they produce — CBG could theoretically complement existing therapies or offer an alternative for patients who don't respond well to current options.

The 98% reduction in IL-6 is particularly noteworthy. IL-6 is one of the most important inflammatory cytokines in RA pathology, and several approved biologic drugs — including tocilizumab (Actemra) — work specifically by blocking it. A plant-derived, non-intoxicating compound achieving comparable suppression in a preclinical model deserves serious attention, even with all the appropriate caveats about the distance between lab results and clinical application.

The Broader Cannabinoid-Arthritis Connection

This study doesn't exist in isolation. A growing body of research supports the idea that cannabinoids — both intoxicating and non-intoxicating — may have meaningful therapeutic applications for inflammatory and rheumatic conditions.

A 2024 study found that among people with rheumatic conditions including arthritis, more than six in ten patients who used medical cannabis reported substituting it for other medications — including NSAIDs, opioids, sleep aids, and muscle relaxants. Most of those patients said cannabis allowed them to reduce or completely stop using those conventional therapies.

That substitution data matters because many standard RA medications carry significant side-effect profiles. Long-term NSAID use is associated with gastrointestinal damage. Corticosteroids cause bone loss and metabolic disruption. Opioids carry addiction risk. Biologics suppress the immune system in ways that increase infection vulnerability. If cannabinoids can provide meaningful symptom relief with a more tolerable safety profile, the clinical and quality-of-life implications are substantial.

Even CBD has shown promise in related applications. A 2018 study published in Frontiers found that CBD oil alleviated symptoms of osteoarthritis in dogs — a finding that, while not directly applicable to human RA, added to the growing evidence base for cannabinoids as anti-inflammatory agents across species.

Important Caveats

The researchers were appropriately measured in their conclusions, noting that human rheumatoid arthritis "is a highly heterogeneous and chronic condition" and that "further long-term clinical studies are necessary" to confirm CBG's efficacy in actual patient populations. Preclinical results — even impressive ones — don't automatically translate to human therapeutic success. The pharmacokinetics, dosing, delivery methods, and long-term safety of CBG in RA patients all remain unknown.

It's also worth noting that Raphael Pharmaceutical Inc., which supplied the CBG used in the study, provided partial funding for the research. That doesn't invalidate the findings, but it's a disclosure that belongs in any honest assessment of the data.

The Bigger Picture

CBG remains one of the least studied major cannabinoids, largely because it's present in most cannabis strains in very small quantities — typically less than 1% by weight. But breeding programs and extraction technology have made CBG-rich products increasingly available, and research interest is growing rapidly.

For the cannabis industry, studies like this one serve a purpose beyond academic curiosity. They build the evidence base that supports cannabis's transition from a consumer product to a legitimate therapeutic platform — exactly the kind of evolution that federal rescheduling, FDA pathways, and pharmaceutical development programs are designed to facilitate.

CBG may never replace methotrexate or tocilizumab. But if it can meaningfully reduce inflammation through a mechanism that no current drug specifically addresses, it deserves a place in the conversation — and a path to the clinical trials that would prove it.

The mother cannabinoid is making her case.

Source: Marijuana Moment

📈 Dog Walkers

$GLASF ( ▼ 1.8% ) Investor Sesh Is On Deck

Glass House Brands is inviting shareholders to see where their money grows — literally.

The company announced its fifth annual Investor Sesh will be held June 18, 2026 at its flagship Camarillo SoCal facility, which Glass House calls the largest cannabis farm in the United States. The event doubles as the company's Annual General Meeting, starting at 11 AM PST, followed by a facility tour, refreshments, and Glass House products available for purchase.

CEO Kyle Kazan framed the event as both a transparency exercise and a thank-you to loyal investors: "We work for our shareholders and always enjoy touring them around their beautiful farm." He noted that the company receives valuable feedback at each year's gathering and takes it seriously.

For Glass House, the timing is strategic. The company is in the middle of a major capacity expansion, has completed the Greenhouse 2 buildout, filed for DEA registration of its medical operations, and recently launched a $50 million ATM equity program — all while navigating a challenging Q1 that saw margin compression and negative adjusted EBITDA. Giving investors an in-person look at the operational progress behind those numbers is a smart move when the financial story requires patience.

Registration is available through the company's investor relations page.

🗞️ The News

📺 Trade To Black

FundCanna’s $60M Move + The Rise Of Pharma-Grade CBD | TTB Presented by Flowhub

• Institutional Capital Arrives: FundCanna secured a $60 million credit facility from a global investment firm managing ~$40 billion in assets — a landmark signal that institutional money is beginning to flow into cannabis lending.

• Cannabis Lending Expansion: The facility supports unsecured credit, AR/AP financing, and broader lending capabilities, expanding access to capital for cannabis operators as federal reform momentum builds.

• Vantage Standard Series: Deepank Utkhede and Christian Santi from Vantage Hemp break down what separates standard CBD companies from those building pharmaceutical-grade cannabinoid infrastructure — including FDA Drug Master Files, global GMP certifications, and clinical trial readiness.

• The Gap Is Wide: From ICH Q7 compliance to healthcare integration, Vantage is positioning for a regulated pharmaceutical cannabinoid future that most of the industry isn't remotely prepared for.